Current treatments for infantile hemangiomas

Journal of Drugs in Dermatology

Volumn 9, Issue 2, 2010, Pages 176-180

  Akhavan, Alaleh ^a   Zippin, Jonathan H ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ALPHA INTERFERON; BETAMETHASONE; CORTICOSTEROID; DEXAMETHASONE; HYDROCHLOROTHIAZIDE; IMIQUIMOD; METHYLPREDNISOLONE SODIUM SUCCINATE; PREDNISOLONE; PREDNISONE; PROPRANOLOL; STEROID; TRIAMCINOLONE; VINCRISTINE; AMINOQUINOLINE DERIVATIVE;

ADRENAL INSUFFICIENCY; AGITATION; AIRWAY HEMANGIOMA; ATROPHY; BLOOD PRESSURE; BODY HEIGHT; BRADYCARDIA; BRONCHOSPASM; CANCER INCIDENCE; CANCER SURGERY; CAPILLARY HEMANGIOMA; CEREBRAL PALSY; CHILDHOOD CANCER; CONSTIPATION; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPIGMENTATION; ERYTHEMA; EYE INJURY; FACIAL NERVE PARALYSIS; FAT ATROPHY; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GROWTH RETARDATION; HEMANGIOMA; HUMAN; HYPERTENSION; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; HYPOGLYCEMIA; HYPOPIGMENTATION; HYPOTENSION; INSOMNIA; META ANALYSIS (TOPIC); MUSCLE HYPERTONIA; NIGHTMARE; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PIGMENT DISORDER; PULSED DYE LASER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA ARTERY OCCLUSION; RETROSPECTIVE STUDY; REVIEW; SCAR FORMATION; SIDE EFFECT; SKIN ATROPHY; SKIN CRUSTING; SKIN DISCOLORATION; SKIN DISEASE; SKIN NECROSIS; SKIN PAIN; SKIN ULCER; SPASTICITY; SUPRAVENTRICULAR TACHYCARDIA; SWEATING; TELANGIECTASIA; THROMBOCYTOPENIA; THYROTOXICOSIS; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR REGRESSION; TUMOR VOLUME; WEIGHT GAIN; WHEEZING; INFANT; LOW LEVEL LASER THERAPY; NEWBORN;

ADRENAL CORTEX HORMONES; AMINOQUINOLINES; HEMANGIOMA; HUMANS; INFANT; INFANT, NEWBORN; INTERFERON-ALPHA; LASER THERAPY; PROPRANOLOL; VINCRISTINE;

EID: 77949894333     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Jacobs AH, Walton RG. The incidence of birthmarks in the neonate. Pediatrics.1976;58:218.
2. Kilcline C, Frieden IJ. Infantile hemangiomas: How common are they? A systematic review of the literature. Pediatr Dermatol. 2008;25:168.
3. Mulliken J, Young A. Vascular Birthmarks: Hemangiomas and Malformations. Philadelphia, PA: WB Saunders; 1988:41-62.
4. Esterly NB. Cutaneous hemangiomas, vascular stains and malformations, and associated syndromes. Curr Probl Dermatol. 1995;7:69-107.
5. Amir J, Metzker A, Krikler R, Reisner SH. Strawberry hemangioma in preterm infants. Pediatr Dermatol.1986;3:331-332. (Pubitemid 17199330)
6. Haggstrom AN, Drolet BA, Baselga E, et al. Prospective study of infantile hemangiomas: Demographic, prenatal and perinatal characteristics. J Pediatr. 2007;150:291-294. (Pubitemid 46328964)
7. Burton BK, Schulz CJ, Angle B, Burd LI. An increased incidence of hemangiomas in infants born following chorionic villus sampling (CVS). Prenat Diagn. 1995;15:209-214.
8. Bruckner AL, Frieden IJ. Hemangiomas of infancy. J Am Acad Dermatol. 2003;48(4):477-493. (Pubitemid 36397008)
9. Tanner JL, Dechert MP, Frieden IJ. Growing up with a facial hemangioma: Parent and child coping and adaptation. Pediatrics. 1998;101(3 Pt 1):446-452. (Pubitemid 28136421)
10. Williams EF III, Hochman M, Rodgers BJ, et al. A psychological profile of children with hemangiomas and their families. Arch Facial Plast Surg. 2003;5(3):229-234.
11. Haggstrom AN, Drolet BA, Baselga E, et al. Prospective study of infantile hemangiomas: Clinical characteristics predicting complications and treatment. Pediatrics. 2006;118:882-887. (Pubitemid 46091612)
12. Boon LM, Bataille AC, Bernier V, et al. Medical treatment of juvenile hemangiomas. Ann Chir Plast Esthet. 2006;51:310-320.
13. Zarem HA, Edgerton MT. Induced resolution of cavernous hemangiomas following prednisolone therapy. Plast Reconstr Surg. 1967;39:76-83.
14. Frieden IJ, Eichenfield LF, Esterly NB, et al. Guidelines of care for hemangiomas of infancy. American Academy of Dermatology Guidelines/Outcomes Committee. J Am Acad Dermatol. 1997;37(4):631-637.
15. Hasan Q, Tan ST, Xu B, Davis PF. Effects of five commonly used glucocorticoids on hemangioma in vitro. Clin Exp Pharmacol Physiol. 2003;30:140-144. (Pubitemid 36343935)
16. Pope E, Krafchik BR, Macarthur C, et al. Oral versus high-dose pulse corticosteroids for problematic infantile hemangiomas: A randomized, controlled trial. Pediatrics. 2007;119(6):e1239-e1247. (Pubitemid 46871240)
17. Metry DW, Hebert AA. Benign cutaneous vascular tumors of infancy: When to worry, what to do. Arch Dermatol. 2000;136:905.
18. Williams EF 3rd, Stanislaw P, Dupree M, et al. Hemangiomas in infants and children. An algorithm for intervention. Arch Facial Plast Surg. 2000;2(2):103-111.
19. Bennett ML, Fleischer AB Jr, Chamlin SL, Frieden IJ. Oral corticosteroid use is effective for cutaneous hemangiomas: An evidence-based evaluation. Arch Dermatol. 2001;137:1208-1213. (Pubitemid 32847844)
20. Rossler J, Wehl G, Niemeyer CM. Evaluating systemic prednisone therapy for proliferating haemangioma in infancy. Eur J Pediatr. 2008;167(7):813-815. (Pubitemid 351733500)
21. Pandey A, Gangopadhyay AN, Gopal SC, et al. Twenty years' experience of steroids in infantile hemangioma - A developing country perspective. J Ped Surg. 2009;44:688-694.
22. Boon LM, MacDonald DM, Mulliken JB. Complications of systemic corticosteroid therapy for problematic hemangioma. Plast Reconstr Surg. 1999;104:1616.
23. George ME, Sharma V, Jacobson J, et al. Adverse effects of systemic glucocorticosteroid therapy in infants with hemangiomas. Arch Dermatol. 2004;140:963.
24. Lomenick JP, Reifschneider KL, Lucky AW, et al. Prevalence of adrenal insufficiency following systemic glucocorticoid therapy in infants with hemangiomas. Arch Dermatol. 2009;145(3):262-266.
25. Chantharatanapiboon W. Intralesional corticosteroid therapy in hemangiomas: Clinical outcome in 160 cases. J Med Assoc Thai. 2008;91 Suppl 3:S90-S96.
26. Chen MT, Yeong EK, Horng SY. Intralesional corticosteroid therapy in proliferating head and neck hemangiomas: A review of 155 cases. J Pediatr Surg. 2000;35:420-423. (Pubitemid 30131602)
27. Drolet BA, Esterly NB, Frieden IJ. Hemangiomas in children. N Engl J Med. 1999;341:173.
28. Chowdri NA, Darzi MA, Fazili Z, et al. Intralesional corticosteroid therapy for childhood cutaneous hemangiomas. Ann Plast Surg. 1994;33(1):46-51. (Pubitemid 24208676)
29. Sloan GM, Reinisch JF, Nichter LS, et al. Intralesional corticosteroid therapy for infantile hemangiomas. Plast Reconstr Surg. 1989;83(3):459-467.
30. Ranchod TM, Frieden IJ, Fredrick DR. Corticosteroid treatment of periorbital haemangioma of infancy: A review of the evidence. Br J Ophthalmol. 2005;89(9)1134-1138. (Pubitemid 41224462)
31. Cruz OA, Zarnegar SR, Myers SE. Treatment of periocular capillary hemangioma with topical clobetasol propionate. Ophthalmology. 1995;102:2012-2015. (Pubitemid 26004461)
32. Garzon MC, Lucky AW, Hawrot A, et al. Ultrapotent topical corticosteroid treatment of hemangiomas of infancy. J Am Acad Dermatol. 2005;52:281-286.
33. Martinez MI, Sanchez-Carpintero I, North PE, Mihm MC. Infantile hemangioma: Clinical resolution with 5% imiquimod cream. Arch Dermatol. 2002;138:881-884. (Pubitemid 34700733)
34. Welsh O, Olazaran Z, Gomez M, et al. Treatment of infantile hemangiomas with short-term application of imiquimod 5% cream. J Am Acad Dermatol. 2004;51:639-642. (Pubitemid 39278088)
35. Hazen PG, Carney JF, Engstrom CW, et al. Proliferating hemangioma of infancy: Successful treatment with topical 5% imiquimod cream. Pediatr Dermatol. 2005;22:254-256. (Pubitemid 40741266)
36. Ho NT, Lansang P, Pope E. Topical imiquimod in the treatment of infantile hemangiomas: A retrospective study. J Am Acad Dermatol. 2007;56(1):63-68. (Pubitemid 46016997)
37. McCuaig CC, Dubois J, Powell J, et al. A phase II, open-label study of the efficacy and safety of imiquimod in the treatment of superficial and mixed infantile hemangioma. Pediatr Dermatol. 2009;26(2):203-212.
38. Ezekowitz RA, Mulliken JB, Folkman J. Interferon alfa-2a treatment for life threatening hemangiomas of infancy. N Engl J Med. 1992;326:1456-1463.
39. Greinwald JH Jr, Burke DK, Bonthius DJ, et al. An update on the treatment of hemangiomas in children with interferon alfa-2a. Arch Otolaryngol Head Neck Surg. 1999;125(1):21-27. (Pubitemid 29074891)
40. Dubois J, Herson L, Carmant L, et al. Toxicity profile of interferon alfa-2b in children: A prospective evaluation. J Pediatr. 1999;135:782-785. (Pubitemid 30180434)
41. Barlow CF, Priebe CJ, Mulliken JB, et al. Spastic diplegia as a complication of interferon alfa-2a treatment of hemangiomas of infancy. J Pediatr. 1998;132:527-530. (Pubitemid 28180264)
42. Michaud AP, Bauman NM, Burke DK, et al. Spastic diplegia and other motor disturbances in infants receiving interferon-alpha. Laryngoscope. 2004;114:1231.
43. Adams DM. The nonsurgical management of vascular lesions. Facial Plast Clin North Am. 2001;9(4):601-608.
44. Perez J, Pardo J, Gomez C. Vincristine - An effective treatment of corticoid resistant life-threatening infantile hemangiomas. Acta Oncol. 2002;41(2):197-199. (Pubitemid 34557083)
45. Perez Payarols J, Pardo Masferrer J, Gomez Bellvert C. Treatment of life-threatening infantile hemangiomas with vincristine. N Engl J Med. 1995;333(1):369.
46. Moore J, Lee M, Garzon M, et al. Effective therapy of a vascular tumor of infancy with vincristine. J Pediatr Surg. 2001;36(8):1273-1276. (Pubitemid 32705723)
47. Fawcett SL, Grant I, Hall PN, et al. Vincristine as a treatment for a large haemangioma threatening vital functions. Br J Plast Surg. 2004;57(2):168-171. (Pubitemid 38239893)
48. Buckmiller L. Update on Hemangiomas and vascular malformation. Curr Opin Otolaryngol Head Neck Surg. 2004;12(6):476-487.
49. Boehm DK, Kobrinsky NL. Treatment of cavernous hemangioma with vincristine. Ann Pharmacother. 1993;27:981.
50. Nguyen J, Fay A. Pharmacologic therapy for periocular infantile hemangiomas: a review of the literature. Semin Opthalmol. 2009;24(3):178-184.
51. Ashinoff R, Geronemus RG. Capillary hemangiomas and treatment with flash lamp-pumped pulsed dye laser. Arch Dermatol. 1991;127(2):202-205.
52. Garden JM, Bakus AD, Paller AS. Treatment of cutaneous hemangiomas by the flashlamp-pumped pulsed dye laser: Prospective analysis. J Pediatr. 1992;120(4 pt 1):555-560.
53. Hohenleutner S, Badur-Ganter E, Landthaler M, Hohenleutner U. Long-term results in the treatment of childhood hemangioma with the flashlamp-pumped pulsed dye laser: An evaluation of 617 cases. Lasers Surg Med. 2001;28(3):273-277. (Pubitemid 32275297)
54. Ashinoff R, Geronemus RG. Failure of the flashlamp-pumped pulsed dye laser to prevent progression to deep hemangioma. Pediatr Dermatol.1993;10(1):77- 80. (Pubitemid 23143924)
55. David LR, Malek MM, Argenta LC. Efficacy of pulse dye laser therapy for the treatment of ulcerated hemangiomas: A review of 78 patients. Br J Plast Surg. 2003;56(4):317-327. (Pubitemid 36927263)
56. Frieden IJ. Which hemangiomas to treat and how? Arch Dermatol. 1997;133(12):1593-1595.
57. Batta K, Goodyear HM, Moss C, et al. Randomised controlled study of early pulsed dye laser treatment of uncomplicated childhood haemangiomas: Results of a one-year analysis. Lancet. 2002;360(9332):521-527. (Pubitemid 35232105)
58. Witman PM, Wagner AM, Scherer K, et al. Complications following pulsed dye laser treatment of superficial hemangiomas. Lasers Surg Med. 2006;38(2):116-123.
59. Dinehart SM, Kincannon J, Geronemus R. Hemangiomas: Evaluation and treatment. Dermatol Surg. 2001;27(5):475-485. (Pubitemid 32436341)
60. Enjolras O, Mulliken JB.The current management of vascular birthmarks. Pediatr Dermatol. 1993;10(4):311-313.
61. McHeik JN, Renauld V, Duport G, et al. Surgical treatment of haemangioma in infants. Br J Plast Surg. 2005;58(8):1067-1072. (Pubitemid 41700386)
62. Buckmiller LM. Update on hemangiomas and vascular malformations. Curr Opin Otolaryngol Head Neck Surg. 2004(12):476-487. (Pubitemid 39565201)
63. Mulliken JB, Rogers GF, Marler JJ. Circular excision of hemangioma and purse-string closure: The smallest possible scar. Plast Reconstr Surg. 2002;109(5):1544-1555.
64. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, et al. Propanolol for severe hemangiomas of infancy. N Engl J Med. 2008;358(24):2649-2651.
65. Sans V, Dumas de la Roque E, Berge J, et al. Propranolol for severe infantile hemangiomas: Follow-up report. Pediatrics. 2009;124:e423-e431.
66. Denoyelle F, Leboulanger N, Enjolras O, et al. Role of Propanolol in the therapeutic strategy of infantile laryngotracheal hemangioma. Int J Pediatr Otorhinolaryngol. 2009;73(8):1168-1172.
67. Buckmiller L, Dyamenahalli U, Richter GT. Propranolol for airway hemangiomas: case report of novel treatment. Laryngoscope. 2009;119(10):2051- 2054.
68. Marsciani A, Pericoli R, Alaggio R et al. Massive response of severe infantile hepatic hemangioma to propanolol. Pediatr Blood Cancer. 2010;54(1):176.
69. Bigorre M, Van Kien AK, Valette H. Beta-blocking agent for treatment of infantile hemangioma. Plast Reconstr Surg. 2009;123(6):e195-e196.
70. Theletsane T, Redfern A, Raynham O, et al. Life-threatening infantile haemangioma: a dramatic response to propranolol. J Eur Acad Dermatol Venereol. 2009;23(12):1465-1466.
71. Mousa W, Kues K, Haas E, et al. Successful treatment of a large hemangioma with propranolol. J Dtsch Dermatol Ges. 2009 [ahead of print].
72. Jephson CG, Manunza F, Syed S, et al. Successful treatment of isolated subglottic haemangioma with propranolol alone. Int J Pediatr Otorhinolaryngol. 2009;73(12):1821-1823.
73. D'Angelo G, Lee H, Weiner RI. camp-dependent protein kinase inhibits the mitogenic action of vascular endothelial growth factor and fibroblast growth factor in capillary endothelial cells by blocking Raf activation. J Cell Biochem. 1997;67:353-366. (Pubitemid 27509471)
74. Sommers Smith SK, Smith DM. Beta blockade induces apoptosis in cultured capillary endothelial cells. In Vitro Cell Dev Biol Anim. 2002;38:298-304. (Pubitemid 35204978)
75. Rouget C, Barthez O, Goirand F, et al. Stimulation of the ADRB3 adrenergic receptor induces relaxation of human placental arteries: Influence of preeclampsia. Biol Reprod. 2006;74(1):209-216. (Pubitemid 43068810)
76. North PE, Waner M, Mizeracki A, et al. A unique microvascular phenotype shared by juvenile hemangiomas and human placenta. Arch Dermatol. 2001;137:559-570. (Pubitemid 32458438)
77. Lawley LP, Siegfried E, Todd JL. Propranolol treatment for hemangioma of infancy: Risks and recommendations. Pediatr Dermatol. 2009;26(5):610-614.
78. Frieden IJ, Drolet BA. Propranolol for infantile hemangiomas: promise, peril, pathogenesis. Pediatr Dermatol. 2009;26(5):642-644.
79. Love JN, Sikka N. Are 1-2 tablets dangerous? Beta blocker exposure in toddlers. J Emerg Med. 2004;26(3)309-314. (Pubitemid 38340830)
80. Fraser K. 67th annual meeting of the American Academy of Dermatology: San Francisco, California, USA. March 6-10, 2009. Am J Clin Dermatol. 2009;10(3):205-210.